全球維生素 D 治療市場 - 2022-2029
市場調查報告書
商品編碼
1143415

全球維生素 D 治療市場 - 2022-2029

Global Vitamin D Therapy Market - 2022-2029

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

預計維生素 D 治療市場在預測期間(2022-2029 年)將以 12.2% 的複合年增長率增長。

維生素 D 是一種脂溶性維生素,身體會因皮膚暴露在陽光下而產生。它也天然存在於一些食物中,如魚、魚肝油、蛋黃、強化乳製品和穀物產品。維生素 D 對支持體內鈣代謝至關重要。通過從食物和補充劑中吸收鈣來支持維持健康的骨細胞。維生素 D 還支持肌肉健康、參與免疫系統、幫助細胞生長、調節血壓並支持心血管健康。血清維生素 D 水平低於 20 ng/mL 的人有維生素 D 缺乏的風險。血清維生素 D 水平低於 12 ng/mL 表明維生素 D 缺乏。缺乏維生素 D 會導致糖尿病、癌症、佝僂病、骨質疏鬆症、腎病等。

市場動態

市場增長的驅動因素是人們對維生素 D 缺乏症的認識不斷提高、人口老齡化加劇、飲食不均衡、肥胖、久坐不動的生活方式等。

預計全球維生素 D 缺乏症的日益流行將推動市場增長。

維生素 D 缺乏症與多種慢性和傳染病有關。根據文獻,這種缺陷的流行可能因地域而異。包括沙特阿拉伯在內的中東和北非地區的維生素 D 不足率相對較高,所有年齡組的維生素 D 不足率為 82%。全球對維生素 D 缺乏症的認識不斷提高是影響市場的主要因素。此外,美國國立衛生研究院 (NIH) 膳食補充劑辦公室 (ODS) 贊助並資助了許多研究,以促進對維生素 D 對健康價值的科學認識。

此外,增加研發以擴大維生素 D 治療的使用預計將在未來推動市場。美國食品和藥物管理局最近批准增加可作為可選成分添加到牛奶中的維生素 D 的含量,並且還添加了許多其他牛奶替代品,包括大豆、杏仁和椰子飲料,以及可食用植物基飲料酸奶替代品。批准在可食用植物製成的飲料中添加維生素 D。因此,從上述陳述來看,預計它將成為預測期內市場的驅動力。

限制

全球品牌的存在和可用性、來自本地和國家品牌的激烈或激烈競爭所帶來的挑戰是預測期內可能阻礙市場發展的方面。

行業分析

維生素 D 治療市場根據各種行業因素(包括未滿足的需求、定價分析、供應鏈分析和監管分析)對市場進行深入分析。

細分分析

在維生素 D 治療市場中,預計口服部分將佔據最大的市場份額。

2021 年,口腔領域將佔據最大的市場份額。該部門受益於給藥方便、藥代動力學和藥效學性能改善、毒性風險降低、患者耐受性提高和對口服途徑的偏好等原因。口服途徑是最常見和批准的給藥途徑。最簡單、最方便、最安全的方式。它是無痛的,患者可以作為片劑服用或與食物混合服用。因此,從上述描述來看,市場細分在預測期內佔據了最大的市場份額。

區域分析

預計北美將佔據全球維生素 D 治療市場的最大市場份額。

北美將在 2021 年佔銷售額的最高份額。維生素 D 缺乏症和骨質疏鬆症等慢性病病例不斷增加、公眾意識、政府支持政策、高額報銷等等。據 IOF 稱,骨質疏鬆症和低骨量對大約 4400 萬 50 歲及以上的美國女性和男性構成重大的公共健康威脅。此外,雅培在 2021 年被評為維生素 D 缺乏症治療頂□□級品牌,在研發方面投入最多,並以可承受的成本提供尖端治療。這增加了該地區對維生素 D 治療的需求。因此,從上述描述來看,北美地區在預測期內佔據了最大的市場份額。

競爭格局

維生素 D 治療市場的主要關鍵參與者是:雅培、賽諾菲、葛蘭素史克、輝瑞公司、默克公司、Torrent Pharmaceuticals、諾華國際公司、Alkem 實驗室、Sun Pharmaceutical Industries 和 Cadila Healthcare Ltd. (Abbott)。

雅培實驗室

概述

Abbott Laboratories 是一家美國跨國醫療器械和醫療保健公司,擁有廣泛而多元化的醫療保健產品發現、開發、製造和營銷組合。 2013 年,我們將研發製藥業務拆分為 AbbVie。我們通過以下部門獲利:藥物、營養學、診斷學、心血管和神經調節劑等。醫療器械、診斷和營養領域的知名產品包括 Pedialyte、Similac、Ensure、Glucerna、ZonePerfect、FreeStyle Libre、i-STAT 和 MitraClip。 190,000 名員工為 160 多個國家的人們提供服務。

產品組合

Avocal: 預防鈣、維生素 D、維生素 C 和維生素 B6 缺乏症,通過減少飲食中維生素 C、維生素 D 和維生素 B6 的攝入量來治療缺乏症。

本報告提供了超過 45 個 市場數據表、超過 40 個圖表和 180 頁有關全球維生素 D 治療市場的信息。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按管理途徑劃分的市場細分
  • 按應用劃分的市場細分
  • 按分銷渠道劃分的市場細分
  • 按地區劃分的市場細分
  • DataM CLO 場景

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 提高對維生素 D 缺乏症的認識
      • 老年人口增加
      • 飲食不均衡
      • 肥胖
      • 久坐不動的生活方式
    • 約束因素
      • 普通消費者缺乏認識
      • 與外部攝入補充劑相關的副作用
    • 商機
    • 影響分析

第5章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析
  • 流行病學

第 6 章給藥途徑

  • 口語
  • 腸胃外
  • 局部給藥

第 7 章按應用程序

  • 骨質疏鬆症
  • 佝僂病
  • 皮膚病
  • 肌肉無力
  • 自身免疫性疾病
  • 其他

第 8 章按銷售渠道

  • 醫院藥房
  • 零售藥房
  • 在線藥店

第 9 章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 10 章競爭格局

  • 競爭場景
  • 競爭性維生素 D 治療策略分析
  • 比較產品組合分析
  • 市場情況/份額分析
  • 併購分析

第 11 章公司簡介

  • 雅培
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Sanofi
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Torrent Pharmaceuticals Ltd.
  • Novartis International AG
  • Alkem Laboratories
  • Sun Pharmaceutical Industries
  • Cadila Healthcare Ltd.

第12章 重要考察

第13章 DataM

簡介目錄
Product Code: DMPH1890

Market Overview

Vitamin D Therapy Market is expected to grow at a CAGR of 12.2% during the forecasting period (2022-2029).

Vitamin D is a fat-soluble vitamin produced by the body in response to skin being exposed to sunlight. It also occurs naturally in a few foods such as fish, fish liver oils, egg yolks, and fortified dairy and grain products. Vitamin D is essential for supporting calcium metabolism in the body. It helps the body absorb calcium from food and supplements to support the maintenance of healthy bone cells. Vitamin D also supports muscle health, plays a role in the immune system, aids cell growth, regulates blood pressure, and supports cardiovascular health. People with less than 20 ng/mL serum vitamin D levels are at risk for vitamin D deficiency. Serum levels below 12 ng/mL indicate a vitamin D deficiency. Vitamin D deficiency can cause diabetes, cancer, rickets, osteoporosis, and kidney diseases.

Market Dynamics

The market growth is driven by growing awareness about vitamin D deficiency, a rise in the geriatric population, an imbalanced diet, obesity, and a sedentary lifestyle.

Increasing vitamin D deficiencies worldwide is expected to drive market growth.

Vitamin D deficiency is linked to various chronic and infectious diseases. According to the literature, the prevalence of this deficit can vary geographically. The Middle East and North African region, which includes Saudi Arabia, has a comparatively high rate of vitamin D insufficiency, with 82% of all age groups deficient. Increased global awareness of vitamin D deficiency is a major factor influencing the market. Moreover, the National Institutes of Health (NIH) Office of Dietary Supplements (ODS) sponsored and funded a number of studies to improve scientific understanding of vitamin D's value to health.

Furthermore, increased R&D to expand the uses of vitamin D treatment is projected to help the market gain traction in the future years. The US Food and Drug Administration recently approved an increase in the amount of vitamin D that can be added as an optional ingredient to milk, as well as the addition of vitamin D to beverages made from edible plants that are intended to be milk substitutes, such as soy, almond, and coconut beverages, and edible plant-based yogurt alternatives. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

The presence and availability of global brands, as well as the challenges they encounter due to big or scant competition from local and domestic brands, are aspects the market is likely to be hampered by during the forecast period.

Industry Analysis

The vitamin D therapy market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

Segment Analysis

Oral segment is expected to hold the largest market share in the vitamin D therapy market.

The oral segment accounted for the largest market share in 2021. The segment benefited because of the convenience of administration, increased pharmacokinetic and pharmacodynamic performance, lower toxicity risk, improved patient tolerance, and a preference for the oral route. The oral route is the most common and approved route for pharmaceutical administration. It is the simplest, most convenient, and most secure method. It is not painful, and the patient can take it as tablets or mix it with food. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North American region is expected to hold the largest market share in the global vitamin D therapy market.

North America accounted for the highest revenue share in 2021. Rise in cases of vitamin D deficiency and other chronic diseases such as osteoporosis, public awareness, supportive government policies, and high reimbursement. According to IOF, osteoporosis and low bone mass are significant public health threats for almost 44 million U.S. women and men aged 50 and older. Moreover, Abbot was named the leading brand in Vitamin D insufficiency treatment in 2021, with the most money invested in research and development and providing cutting-edge treatments at accessible costs. Therefore, it has increased the demand for Vitamin D therapy in the region. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the vitamin D therapy market are: Abbott, Sanofi, GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Inc., Torrent Pharmaceuticals, Novartis International AG, Alkem Laboratories, Sun Pharmaceutical Industries, and Cadila Healthcare Ltd.

Abbott Laboratories:

Overview:

Abbott Laboratories is an American multinational medical device and healthcare company that explores, develops, manufactures, and sells a broad and diversified line of healthcare products. It split off its research-based pharmaceuticals business into AbbVie in 2013. It benefits through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Others. Its well-known products across the medical devices, diagnostics, and nutrition divisions are Pedialyte, Similac, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT and MitraClip. One hundred nine thousand colleagues serve people in more than 160 countries.

Product Portfolio:

ABOCAL: To help prevent deficiencies of Calcium, vitamin D, vitamin C and vitamin B6, for the treatment of deficiency state resulting from reduced intake of vitamin C, vitamin D and vitamin B6 in the diet.

The global vitamin D therapy market report would provide an access to an approx. 45+ market data table, 40+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Route of Administration
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region
  • 3.5. DataM CLO Scenario

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing awareness about vitamin D deficiency
      • 4.1.1.2. Rise in geriatric population
      • 4.1.1.3. Imbalanced diet
      • 4.1.1.4. Obesity
      • 4.1.1.5. Sedentary life style
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of awareness among the common population
      • 4.1.2.2. Side effects associated with external intake of supplements
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Epidemiology

6. By Route of Administration

  • 6.1. Introduction
  • 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 6.3. Market Attractiveness Index, By Route of Administration
  • 6.4. Oral
    • 6.4.1. Introduction
    • 6.4.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 6.5. Parenteral
  • 6.6. Topical

7. By Application

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 7.3. Market Attractiveness Index, By Application
  • 7.4. Osteoporosis
    • 7.4.1. Introduction
    • 7.4.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026
  • 7.5. Rickets
  • 7.6. Skin Diseases
  • 7.7. Muscle Weakness
  • 7.8. Autoimmune Disorders
  • 7.9. Others

8. By Distribution Channel

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.3. Market Attractiveness Index, By Distribution Channel
  • 8.4. Hospital pharmacies
    • 8.4.1. Introduction
    • 8.4.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026
  • 8.5. Retail pharmacies
  • 8.6. Online pharmacies

9. By Region

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 9.3. Market Attractiveness Index, By Region
  • 9.4. North America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. U.S.
      • 9.4.6.2. Canada
      • 9.4.6.3. Mexico
  • 9.5. Europe
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. Germany
      • 9.5.6.2. U.K.
      • 9.5.6.3. France
      • 9.5.6.4. Italy
      • 9.5.6.5. Spain
      • 9.5.6.6. Rest of Europe
  • 9.6. South America
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.6.6.1. Brazil
      • 9.6.6.2. Argentina
      • 9.6.6.3. Rest of South America
  • 9.7. Asia-Pacific
    • 9.7.1. Introduction
    • 9.7.2. Key Region-Specific Dynamics
    • 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.7.6.1. China
      • 9.7.6.2. India
      • 9.7.6.3. Japan
      • 9.7.6.4. Australia
      • 9.7.6.5. Rest of Asia Pacific
  • 9.8. Middle East and Africa
    • 9.8.1. Introduction
    • 9.8.2. Key Region-Specific Dynamics
    • 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Competitor Vitamin D Therapy Strategy Analysis
  • 10.3. Comparative Product Portfolio Analysis
  • 10.4. Market Positioning/Share Analysis
  • 10.5. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Abbott *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Sanofi
  • 11.3. GlaxoSmithKline plc
  • 11.4. Pfizer Inc.
  • 11.5. Merck & Co., Inc.
  • 11.6. Torrent Pharmaceuticals Ltd.
  • 11.7. Novartis International AG
  • 11.8. Alkem Laboratories
  • 11.9. Sun Pharmaceutical Industries
  • 11.10. Cadila Healthcare Ltd.

12. Premium Insights

13. DataM Intelligence

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us